Hovione announced the appointment of Dr. Conrad Winters as Director, Drug Product Development. Dr. Winters was previously with Merck and most recently with Xenon Pharmaceuticals, where he held the position of Senior Director, Compound Properties Group.

"We are very pleased to welcome Dr. Winters to Hovione. His experience in particle engineering, solubilisation, drug product development, scale up and commercialization will enable us to solve our customers' most challenging problems", said Dr. Thomas Eisele, Vice President Corporate Research & Development.

"I am delighted to join the strong team at Hovione. Already the recognized world leader in pharmaceutical spray drying, I am looking forward to leading the team in developing complimentary technologies to enable Hovione to offer customers' integrated solutions for any molecule", said Dr. Winters.

Dr. Winters is a Senior Director with 18 years of experience in the pharmaceutical industry. His focus is on managing the development of compounds from lead candidate optimization through to NDA submission and commercialization. He has lots of experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Dr. Winters has led cross functional global teams charged with the development of new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions